je.st
news
Tag: antiviral
As flu becomes more widespread, CDC pushes antiviral meds
2015-01-10 01:43:36| Biotech - Topix.net
This April 30, 2009, file photo shows a box of Tamiflu in a Toronto health clinic. The Centers for Disease Control and Prevention on Friday, Jan. 9. 2015, sent a new alert to doctors, advising prompt use of Tamiflu and other antivirals for hospitalized flu patients and those at higher risk for complications like pneumonia.
Tags: widespread
flu
pushes
cdc
Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients
2014-07-24 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
phase
patients
prevention
BioCryst snags $1.9M for antiviral candidate
2014-06-24 05:28:05| Biotech - Topix.net
The Durham-based company, which is developing an antiviral dubbed BCX4430, had already partnered with the National Institute of Allergy and Infectious Diseases, receiving an initial award of $5 million last September.
Tags: candidate
19m
antiviral
snags
AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients
2014-05-08 15:00:00| Merck.com - Research & Development News
Dateline City: WUPPERTAL, Germany & WHITEHOUSE STATION, N.J. WUPPERTAL, Germany & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--AiCuris and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from a Phase 2 clinical trial evaluating the safety and efficacy of letermovir, an investigational, oral antiviral agent for the prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orInvestors:Carol Ferguson, 908-423-4465orAiCurisMedia:Katja Woestenhemke, +49-202-317-63-1176 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
publication
journal
agent
Mercks Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
2014-04-11 07:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Clinical Findings Support Initiation of C-EDGE Phase 3 Program WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 201-669-6570orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: activity
combination
patients
therapy